{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:04:40Z","timestamp":1790067880346,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/postmj\/qgag129","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:18:41Z","timestamp":1788520721000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond efficacy: health inequities limiting access to semaglutide for obesity management"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6681-3573","authenticated-orcid":false,"given":"Kanwal","family":"Islam","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Nishtar Medical University & Hospital , Nishtar Road, Gillani Colony, Multan , District Multan, Punjab 66000,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2682-9047","authenticated-orcid":false,"given":"Mahmood","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nishtar Medical University & Hospital , Nishtar Road, Gillani Colony, Multan , District Multan, Punjab 66000,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026092204411718000_ref1","first-page":"76:102848","article-title":"Burden of disease attributable to high body mass index: an analysis of data from the global burden of disease study 2021","author":"Zhou","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026092204411718000_ref2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092204411718000_ref3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092204411718000_ref4","volume-title":"WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity","author":"Organization WH","year":"2025"},{"key":"2026092204411718000_ref5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"2026092204411718000_ref6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13690-026-01883-6","article-title":"GLP-1 guidelines amid an obesity epidemic: a poor fit for the global south","volume":"84","author":"Shrisunder","year":"2026","journal-title":"Arch Public Heal"},{"key":"2026092204411718000_ref7","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.2025.4735","article-title":"Uptake of and disparities in semaglutide and tirzepatide prescribing for obesity in the US","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"2026092204411718000_ref8","first-page":"130","article-title":"Socioeconomic and demographic inequalities in off-label prescription of glucagon-like Peptide-1 receptor agonists: a Swedish descriptive cohort study","volume":"18","author":"Pazzagli","year":"2025","journal-title":"Obes Facts"},{"key":"2026092204411718000_ref9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","article-title":"Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity","volume":"30","author":"Waldrop","year":"2024","journal-title":"Nat Med"},{"key":"2026092204411718000_ref10","doi-asserted-by":"crossref","first-page":"e250083","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article-pdf\/doi\/10.1093\/postmj\/qgag129\/71303626\/qgag129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article-pdf\/doi\/10.1093\/postmj\/qgag129\/71303626\/qgag129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:41:24Z","timestamp":1790066484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article\/doi\/10.1093\/postmj\/qgag129\/8826572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgag129","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"qgag129"}}